Waltz Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-12-2024
- Paid Up Capital ₹ 0.10 M
as on 06-12-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -1.42%
(FY 2020)
- Profit 101.38%
(FY 2020)
- Ebitda 65.18%
(FY 2020)
- Net Worth 112.19%
(FY 2020)
- Total Assets -4.56%
(FY 2020)
About Waltz Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jyotsna Yadav, Deepali Singh, and Sanjeev Gupta serve as directors at the Company.
- CIN/LLPIN
U51109DL2009PTC195422
- Company No.
195422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Oct 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Waltz Pharmaceuticals Private Limited offer?
Waltz Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Anti Ulcer Drugs, Pharmaceutical Capsules, Softgel Capsules, Antibiotic Tablets & Capsules, Cefixime Tablet, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Calcium Tablet, Calcium K27.
Who are the key members and board of directors at Waltz Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyotsna Yadav  | Director | 01-Aug-2015 | Current |
| Deepali Singh | Additional Director | 15-Apr-2019 | Current |
| Sanjeev Gupta | Director | 01-May-2023 | Current |
Financial Performance of Waltz Pharmaceuticals.
Waltz Pharmaceuticals Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.42% decrease. The company also saw a substantial improvement in profitability, with a 101.38% increase in profit. The company's net worth Soared by an impressive increase of 112.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Waltz Pharmaceuticals?
In 2018, Waltz Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arunodaya Energy & Infrastructure Private LimitedActive 17 years 7 monthsJyotsna Yadav is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Waltz Pharmaceuticals?
Unlock and access historical data on people associated with Waltz Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Waltz Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Waltz Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
